Smart Nanotherapeutics and Lung Cancer

Lung cancer is a significant health problem worldwide. Unfortunately, current therapeutic strategies lack a sufficient level of specificity and can harm adjacent healthy cells. Consequently, to address the clinical need, novel approaches to improve treatment efficiency with minimal side effects are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohammad Doroudian, Mohammad H. Azhdari, Nima Goodarzi, David O’Sullivan, Seamas C. Donnelly
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	nanomedicine smart nanoparticles nanotherapeutics lung cancer nanodrug delivery targeted drug delivery Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/7ee746ff665b413bb009d2a3de1fb067
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7ee746ff665b413bb009d2a3de1fb067
record_format	dspace
spelling	oai:doaj.org-article:7ee746ff665b413bb009d2a3de1fb0672021-11-25T18:42:33ZSmart Nanotherapeutics and Lung Cancer10.3390/pharmaceutics131119721999-4923https://doaj.org/article/7ee746ff665b413bb009d2a3de1fb0672021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1972https://doaj.org/toc/1999-4923Lung cancer is a significant health problem worldwide. Unfortunately, current therapeutic strategies lack a sufficient level of specificity and can harm adjacent healthy cells. Consequently, to address the clinical need, novel approaches to improve treatment efficiency with minimal side effects are required. Nanotechnology can substantially contribute to the generation of differentiated products and improve patient outcomes. Evidence from previous research suggests that nanotechnology-based drug delivery systems could provide a promising platform for the targeted delivery of traditional chemotherapeutic drugs and novel small molecule therapeutic agents to treat lung cancer cells more effectively. This has also been found to improve the therapeutic index and reduce the required drug dose. Nanodrug delivery systems also provide precise control over drug release, resulting in reduced toxic side effects, controlled biodistribution, and accelerated effects or responses. This review highlights the most advanced and novel nanotechnology-based strategies, including targeted nanodrug delivery systems, stimuli-responsive nanoparticles, and bio-nanocarriers, which have recently been employed in preclinical and clinical investigations to overcome the current challenges in lung cancer treatments.Mohammad DoroudianMohammad H. AzhdariNima GoodarziDavid O’SullivanSeamas C. DonnellyMDPI AGarticlenanomedicinesmart nanoparticlesnanotherapeuticslung cancernanodrug deliverytargeted drug deliveryPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1972, p 1972 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanomedicine smart nanoparticles nanotherapeutics lung cancer nanodrug delivery targeted drug delivery Pharmacy and materia medica RS1-441
spellingShingle	nanomedicine smart nanoparticles nanotherapeutics lung cancer nanodrug delivery targeted drug delivery Pharmacy and materia medica RS1-441 Mohammad Doroudian Mohammad H. Azhdari Nima Goodarzi David O’Sullivan Seamas C. Donnelly Smart Nanotherapeutics and Lung Cancer
description	Lung cancer is a significant health problem worldwide. Unfortunately, current therapeutic strategies lack a sufficient level of specificity and can harm adjacent healthy cells. Consequently, to address the clinical need, novel approaches to improve treatment efficiency with minimal side effects are required. Nanotechnology can substantially contribute to the generation of differentiated products and improve patient outcomes. Evidence from previous research suggests that nanotechnology-based drug delivery systems could provide a promising platform for the targeted delivery of traditional chemotherapeutic drugs and novel small molecule therapeutic agents to treat lung cancer cells more effectively. This has also been found to improve the therapeutic index and reduce the required drug dose. Nanodrug delivery systems also provide precise control over drug release, resulting in reduced toxic side effects, controlled biodistribution, and accelerated effects or responses. This review highlights the most advanced and novel nanotechnology-based strategies, including targeted nanodrug delivery systems, stimuli-responsive nanoparticles, and bio-nanocarriers, which have recently been employed in preclinical and clinical investigations to overcome the current challenges in lung cancer treatments.
format	article
author	Mohammad Doroudian Mohammad H. Azhdari Nima Goodarzi David O’Sullivan Seamas C. Donnelly
author_facet	Mohammad Doroudian Mohammad H. Azhdari Nima Goodarzi David O’Sullivan Seamas C. Donnelly
author_sort	Mohammad Doroudian
title	Smart Nanotherapeutics and Lung Cancer
title_short	Smart Nanotherapeutics and Lung Cancer
title_full	Smart Nanotherapeutics and Lung Cancer
title_fullStr	Smart Nanotherapeutics and Lung Cancer
title_full_unstemmed	Smart Nanotherapeutics and Lung Cancer
title_sort	smart nanotherapeutics and lung cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/7ee746ff665b413bb009d2a3de1fb067
work_keys_str_mv	AT mohammaddoroudian smartnanotherapeuticsandlungcancer AT mohammadhazhdari smartnanotherapeuticsandlungcancer AT nimagoodarzi smartnanotherapeuticsandlungcancer AT davidosullivan smartnanotherapeuticsandlungcancer AT seamascdonnelly smartnanotherapeuticsandlungcancer
_version_	1718410782507532288

Smart Nanotherapeutics and Lung Cancer

Ejemplares similares